Resources
40 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 11/28/2023 (updated 3/28/2024)
Substance use is a major health issue among individuals in custody, and for these individuals, withdrawal from substances can be life-threatening. Jurisdictions have a pressing responsibility to save lives by implementing policies and protocol that align with legal, regulatory, and clinical standards related to appropriate withdrawal management. Recently released Guidelines for Managing Substance Withdrawal in Jails sets forth best clinical practices and actionable guidance for jails. This presentation discussed readiness for implementation, key components of implementation, and solutions for implementation in local communities and jails.
Learning Objectives:
-Assessed readiness for implementing a comprehensive and appropriate multidisciplinary approach to withdrawal management.
-Discussed action steps for building community support.
-Identified resources for training and technical assistance to implement the Guidelines.
Presenter:
Linda J. Frazier, B.S, M.A., RN, MCHES
Principal Consultant, Advocate for Human Potential, Inc.
Posted 10/27/2023 (updated 3/28/2024)
As announced by the Substance Abuse and Mental Health Services Administration in January 2023, clinicians no longer need a federal waiver to prescribe buprenorphine for treatment of opioid use disorder. Clinicians will still be required to register with the federal Drug Enforcement Agency (DEA) to prescribe controlled medications. On June 27, the DEA began to require that registration applicants – both new and renewing – affirm they have completed a new, one-time, eight-hour training.
Posted 9/8/2023 (updated 3/26/2024)
September 2023 is National Recovery Month and HRSA’s Office of Women’s Health has a toolkit to support organizations and health care providers that care for women living with opioid use disorder (OUD). The toolkit provides strategies to engage women with OUD, care coordination for support, and other resources.
Posted 8/15/2023 (updated 3/26/2024)
During this webinar, Aaron Ferguson and Dr. Janan Wyatt reviewed the evidence, including the cost benefit, of MOUD, and recent research findings on how regulatory changes affect patient experience.
Posted 7/26/2023 (updated 3/28/2024)
This session covered how primary prevention efforts fit within each of the various stages of the Continuum of Care Model. Attendees learned how to (1) engage community stakeholders from each of the 12 sectors and (2) evidence-based practices to not only inform, but to reduce stigma and to create open dialogue as it relates to SUD.
Posted 7/26/2023 (updated 3/28/2024)
This session discussed the barriers typically encountered and workarounds such as money, staff, and location. We encouraged participants to bring successes, near successes, and non-successes in expanding access over the last 3 years.
Posted 7/21/2023 (updated 3/28/2024)
Posted 6/22/2023 (updated 3/28/2024)
The Buncombe Bridge to Care (BB2C): Post-Overdose Buprenorphine Field Initiation Program Toolkit was developed by Buncombe County Emergency Services Community Paramedicine and UNC Health Sciences at Mountain Area Health Education Center (MAHEC). This toolkit describes the project and protocols utilized. It is not intended to be a comprehensive guide or manual, but instead to inspire communities to increase access to lifesaving medication for the marginalized community of people who use drugs.
Posted 5/26/2023 (updated 3/27/2024)
Providers Clinical Support System (PCSS), a Substance Abuse and Mental Health Services Administration-funded grant initiative, announced the release of Practice-Based Guidelines: Buprenorphine in the Age of Fentanyl. The guide gives practitioners a blueprint on treating fentanyl use disorder based on available research combined with emerging clinical experience on the use of buprenorphine in the treatment of individuals using fentanyl and other highly potent synthetic opioids.
Posted 5/26/2023 (updated 3/27/2024)
The U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to sever opioid use disorder (OUD). Buprenorphine is a safe and effective medication for OUD treatment.